Home/Pipeline/SHR-4640

SHR-4640

Gout

Phase IIIActiveNCT05237648

Key Facts

Indication

Gout

Phase

Phase III

Status

Active

Company

Jiangsu Hengrui Medicine

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine's mission is to advance healthcare through high-quality, innovative medicines, solidifying its position as China's largest and most valuable pharmaceutical company. Its key achievements include building a massive pipeline of 719 drug candidates, successfully launching multiple blockbuster oncology drugs in China, and establishing international R&D footprints. The company's strategy centers on aggressive investment in proprietary R&D, a dual-track approach of 'innovation + internationalization,' and dominating key therapeutic areas like oncology while expanding into metabolic, autoimmune, and neurological diseases.

View full company profile

Therapeutic Areas

Oncology Anesthesia Metabolic Disease Autoimmune Disease Cardiovascular

Other Gout Drugs

Drug	Company	Phase	Status
Gout Trial	Well Pharma Medical Research	Not Specified	Active
Gout Research Study with Tophi	West Coast Research	Phase 3/4	Active
Pipeline Program	Novilla Pharmaceuticals	Pre-clinical	Active
Allopurinol Tablets	Indoco Remedies	Approved	Commercial